Cancer Stem Cell News Volume 3.42 | Oct 29 2014

    Cancer Stem Cell News 3.42 October 29, 2014

    Cancer Stem Cell News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  CSCN on Twitter

    Modeling De Novo Leukemogenesis from Human Cord Blood with MN1 and NUP98HOXD13
    Co-transduction of an activated HOX gene with MN1 induces a serially transplantable acute myeloid leukemia (AML). Further characterization of the leukemic cells generated from the dually transduced cells revealed activation of stem cell gene expression signatures also found in primary human AML. [Blood] Abstract
    [Watch the Video] Detect Cancer Stem Cells with ALDEFLUOR™.

    PUBLICATIONS (Ranked by impact factor of the journal)
    Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells
    Researchers tested whether the combination of ABT-737 with 4-HPR is effective in killing both the bulk of melanoma cells and melanoma initiating cells. The combination synergistically decreased cell viability and caused cell death in multiple melanoma cells lines, but not in normal melanocytes. [J Invest Dermatol] Abstract

    HIF-1alpha Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells
    A well characterized murine model of prostate cancer was used to investigate the regulation of hypoxia-inducible factor 1alpha (HIF-1alpha) in cancer stem cells and a basal stem cell subpopulation was identified, in primary prostate tumors of mice, with elevated HIF-1alpha expression. [Mol Cancer Res] Abstract

    High GINS2 Transcript Level Predicts Poor Prognosis and Correlates with High Histological Grade and Endocrine Therapy Resistance through Mammary Cancer Stem Cells in Breast Cancer Patients
    GINS2 expression was significantly downregulated under mutated p53-depleted condition in MDA-468 and MDA-MB-231 cells, upregulated in mammary cancer stem cells, and correlated with upregulated genes in mammary stem cells. [Breast Cancer Res Treat] Abstract

    Methods for Detecting Circulating Cancer Stem Cells (CCSCs) as a Novel Approach for Diagnosis of Colon Cancer Relapse/Metastasis
    Scientists report for the first time the detection of CCSCs in the blood of athymic nude mice, bearing metastatic tumors, and in the blood of patients positive for colonic adenocarcinomas. Using a simple and non-expensive method, they isolated a relatively pure population of CSCs, free of red blood cells and largely free of contaminating CD45+ white blood cells. [Lab Invest] Abstract

    Hepatoma SK Hep-1 Cells Exhibit Characteristics of Oncogenic Mesenchymal Stem Cells with Highly Metastatic Capacity
    Researchers demonstrate that SK Hep-1 cells (SK cells) represent a transformation mechanism of normal mesenchymal stem cells into an enhanced self-renewal cancer stem cells (CSC) with metastasis capacity, SK cells and their xenografts represent a same relative homogeneity of CSC with substantial metastatic capacity. [PLoS One] Full Article

    Bmi1 Regulates Self-Renewal and Epithelial to Mesenchymal Transition in Breast Cancer Cells through Nanog
    Scientists explored the role of Bmi1 in regulating the stemness and drug resistance of breast cancer cells. Bmi1 overexpression in immortalized and transformed breast epithelial cells increased their sphere-forming efficiency, induced epithelial to mesenchymal transition with an increase in the expression of stemness-related genes. [BMC Cancer] Abstract | Full Article

    miR-99a Directly Targets the mTOR Signaling Pathway in Breast Cancer Side Population Cells
    Scientists detected expression of miR-99a in the side population (SP) cells compared to non-SP cells using real-time PCR, and explored effects of miR-99a on the cancer stem cell phenotype of the breast cancer cells, including sphere formation, self-renewal, tumorigenicity and cell migratory capability. [Cell Prolif] Abstract

    Tight Regulation between Cell Survival and Programmed Cell Death in GBM Stem-Like Cells by EGFR/GSK3b/PP2A Signaling
    Investigators evaluated the role of glycogen synthase kinase 3 beta (GSK3b) in patient-derived glioblastoma (GBM) stem-like cell proliferation, apoptosis and invasion. [J Neurooncol] Abstract

    siRNA Targeting Stathmin Inhibits Invasion and Enhances Chemotherapy Sensitivity of Stem Cells Derived from Glioma Cell Lines
    Researchers isolated glioma stem cells (GSCs) from glioma cell lines U87MG and U251, and then used siRNA targeting stathmin for silencing. They show that silencing of stathmin suppressed the proliferation, increased the apoptosis rate, and arrested the cell cycle at G2/M phase in GSCs. [Acta Biochim Biophys Sin] Abstract

    Culture Human Glioma-Derived Tumorspheres with NeuroCult™ - View Publications

    Crosstalk between CTC, Immune System and Hypoxic Tumor Microenvironment
    The authors discuss how hypoxia is involved in the regulation of tumor progression and induction of EMT and cancer stem cell like features. They also illustrate the relationship between hypoxia and circulating tumor cells (CTC) and review how CTC interact with the cells of immune system in terms of their survival and EMT phenotype. [Cancer Microenviron] Abstract

    Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

    Global Controls in Stem Cells

    The Leukemia & Lymphoma Society Launches New Initiative to Halt the Progression of Myeloid Blood Cancers
    The Leukemia & Lymphoma Society has initiated a program to fund research projects seeking to better understand and, ultimately, stop progression of certain types of blood cancers from early-stage malignancies to much more lethal states of disease. [The Leukemia & Lymphoma Society] Press Release

    MEI Pharma Advances Clinical Study of Mitochondrial Inhibitor ME-344 in Small Cell Lung and Ovarian Cancers
    MEI Pharma, Inc. announced that the first patient has been dosed in the cohort-expansion stage of the Company’s Phase Ib clinical study of investigational drug candidate ME-344 in combination with topotecan in patients with small cell lung or ovarian cancer who failed initial therapy. [MEI Pharma, Inc.] Press Release

    Synta Announces Initiation of I-SPY 2 TRIAL of Ganetespib in Breast Cancer
    Synta Pharmaceuticals Corp. announced the initiation of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) arm evaluating ganetespib, the company’s Hsp90 inhibitor, as a neoadjuvant therapy for patients with breast cancer. [Synta Pharmaceuticals Corp.] Press Release

    Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (Pembrolizumab) in Advanced Non-Small Cell Lung Cancer
    Merck announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to KEYTRUDA®, the company’s anti-PD-1 therapy, for the treatment of patients with epidermal growth factor receptor mutation-negative, and anaplastic lymphoma kinase rearrangement-negative non-small cell lung cancer whose disease has progressed on or following platinum-based chemotherapy. [Merck & Co., Inc.] Press Release

    From our sponsor:
    Interested in assays for human mammary stem and progenitor cells?
    Request your free wallchart.

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    NEW 26th EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
    November 18-21, 2014
    Barcelona, Spain

    Visit our events page to see a complete list of events in the cancer stem cell community.

    NEW Postdoctoral Position – Intestinal Stem Cell Biology and Gastrointestinal Malignancies (Albert Einstein College of Medicine of Yeshiva University)

    PhD Student Position – Cancer Biology (Queen Mary University of London)

    Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

    Postdoctoral Fellow – Gene Regulation in Breast Cancer/Stem Cell Biology (UC College of Medicine)

    Postdoctoral Position – Leukemic Stem Cells (BC Cancer Agency)

    Assistant or Associate Professor – Cancer Biology (University of Pennsylvania)

    Faculty Positions – Stem Cells and Regenerative Medicine (Baylor College of Medicine)

    Research Assistant or Research Associate – Stem Cell & Cancer Biology (University of North Texas Health Science Center)

    Postdoctoral Fellow – Stem Cells and Breast Cancer (Albert Einstein College of Medicine in New York)

    Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

    Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

    Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


    Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Cancer Stem Cell News: Archives | Events | Contact Us